Objective
The MOPEAD consortium has proposed a programme of work carefully aligned to the objectives of IMI2 Call to deliver a step-change in AD-related patient engagement (PE) strategies and a paradigm shift in early stage care. It aims to improve patient engagement in three categories: 1) Pre-clinical AD (the most important for prevention trials; 2) Prodromal AD (i.e. MCI with positive amyloid biomarkers); and 3) Very Mild AD. MOPEAD offers four different and complementary strategies, namely AD Citizen-Science, Open House Initiative (OHI), Primary Care Campaign (PCC), and Type 2 Diabetes (T2DM). It seeks subjects eligible for CT scan in all three mentioned categories. The central concept is to test and evaluate the four Patient Engagement models (Runs) to help identify patients at risk of AD in a five-country, multi-centre setting. It builds upon an already successful model, the Open House Initiative pioneered by the coordinator (FACE). Five countries (ES, DE, NL, SE and SL) have been selected to implement these models based upon relevant expertise; the consortium brings together partners for their potential to become long-term assets to European efforts to tackle AD challenges. The methodology involves enhanced pre-screening protocols to select individuals for conventional screening associated to an RCT. Eligible subjects will be invited to formal evaluation using a protocol consensus with EPFIA. MOPEAD possesses confident baseline metrics from which to measure progress and determine the efficacy of PE strategies compared to primary care. Although baseline data exists for only three of the four proposed models, the new model AD Citizen Science approach will add significantly to the holistic approach of the project. The proposal addresses the specific cross-border challenge of improving health care and reducing the economic burden related to AD by means of identifying those patients at risk of developing AD. This will cover a significant gap in the healthcare system.
Fields of science
Not validated
Not validated
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- humanitieshistory and archaeologyhistory
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health sciencesclinical medicineendocrinologydiabetes
- social sciencespolitical sciencespolitical policiescivil society
Programme(s)
Funding Scheme
IMI2-RIA - Research and Innovation actionCoordinator
08014 Barcelona
Spain
See on map
Participants (15)
RG21 4FA Basingstoke
See on map
1160 AUDERGHEM
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
151 85 Sodertaelje
See on map
A96 N9K0 DUBLIN
See on map
28760 Tres Cantos Madrid
See on map
17177 Stockholm
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
104 22 Stockholm
See on map
Participation ended
HD1 3BD Huddersfield
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1000 Ljubljana
See on map
50937 Koeln
See on map
1000 Ljubljana
See on map
08035 Barcelona
See on map
1081 HV Amsterdam
See on map
1736 SENNINGERBERG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
DD2 1TY DUNDEE
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.